S
Satoshi Morita
Researcher at Kyoto University
Publications - 828
Citations - 31983
Satoshi Morita is an academic researcher from Kyoto University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 66, co-authored 751 publications receiving 27042 citations. Previous affiliations of Satoshi Morita include RMIT University & Yokohama City University Medical Center.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi,Masaki Mandai,Takafumi Ikeda,Manabu Minami,Atsushi Kawaguchi,Toshinori Murayama,Masashi Kanai,Yukiko Mori,Shigemi Matsumoto,Shunsuke Chikuma,Noriomi Matsumura,Kaoru Abiko,Tsukasa Baba,Ken Yamaguchi,Akihiko Ueda,Yuko Hosoe,Satoshi Morita,Masayuki Yokode,Akira Shimizu,Tasuku Honjo,Ikuo Konishi +20 more
TL;DR: The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714).
Journal ArticleDOI
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
Tetsuhiro Kikuchi,Asuka Morizane,Daisuke Doi,Hiroaki Magotani,Hirotaka Onoe,Takuya Hayashi,Hiroshi Mizuma,Sayuki Takara,Ryosuke Takahashi,Haruhisa Inoue,Satoshi Morita,Michio Yamamoto,Keisuke Okita,Masato Nakagawa,Malin Parmar,Jun Takahashi +15 more
TL;DR: This preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.